Methods for producing carboxylate ligand modified ferric iron hydroxide colloids and related compositions and uses

Patent metadata

Field	Value
Publication number	US-11684572-B2
Application number	US-202016747821-A
Country	US
Kind code	B2
Filing date	Jan 21, 2020
Priority date	Oct 9, 2015
Publication date	Jun 27, 2023
Grant date	Jun 27, 2023

Abstract

Processes for recovering colloids of carboxylate ligand modified ferric iron hydroxide materials such as IHAT (Iron Hydroxide Adipate Tartrate) are described based on the use of water miscible non-aqueous solvents, such as ethanol, methanol and acetone. The processes produce materials with advantageous properties such as improved bioavailability, reduced aggregation and/or agglomeration and/or increased iron content.

First claim

The invention claimed is:

1. A composition comprising a carboxylate ligand modified ferric iron hydroxide material having a three dimensional polymeric structure in which the carboxylate ligands are non-stoichiometrically substituted for the oxo or hydroxy groups of the ferric iron hydroxide so that some of the ligand integrates into the solid phase by formal metal-ligand bonding,
wherein the three dimensional polymeric structure of the carboxylate ligand modified ferric iron hydroxide is such that the substitution of the oxo or hydroxy groups by the carboxylate ligands is random,
and
wherein the carboxylate ligand modified ferric iron hydroxide material is produced by a method comprising:
(i) mixing a colloidal suspension of the carboxylate ligand modified ferric iron hydroxide in a water miscible non-aqueous solvent to cause the carboxylate ligand modified ferric iron hydroxide to agglomerate;
(ii) recovering the agglomerated carboxylate ligand modified ferric iron hydroxide; and
(iii) drying the carboxylate ligand modified ferric iron hydroxide to produce the carboxylate ligand modified ferric iron hydroxide material;
wherein the carboxylate ligand comprises one or more dicarboxylate ligands of the formula HOOC—R 1 —COOH or an ionised form thereof, wherein R 1 is an optionally substituted C 1-10 alkyl, C 1-10 alkenyl or C 1-10 alkynyl group; and
wherein the water miscible non-aqueous solvent is selected from ethanol, methanol and/or acetone.

2. The composition of claim 1 , wherein the carboxylate ligand modified ferric iron hydroxide material comprises adipate and tartrate ligands or tartrate and succinate ligands or succinate and adipate ligands.

3. The composition of claim 2 , wherein the ligands and ferric iron ions are present in a molar ratio of 1:1:2 (tartrate:adipate:Fe), 1:1:2 (tartrate:succinate:Fe), 1:6:2 (tartrate:succinate:Fe) or 1:1:2 (succinate:adipate:Fe).

4. The composition of claim 1 , wherein the carboxylate ligand modified ferric iron hydroxide material comprises tartrate/tartaric acid ligands.

5. The composition of claim 1 , wherein the carboxylate ligand modified ferric iron hydroxide has an iron content of at least 10% Fe (w/w), or at least 20% Fe (w/w).

6. An iron supplement tablet, capsule or powder comprising the composition of claim 1 .

7. A method for treating iron deficiency anaemia, iron deficiency and anaemia of chronic disease in a patient, the method comprising administering to the patient a therapeutically effective amount of the composition of claim 1 .

8. The method of claim 7 , wherein the composition is administered orally.

9. The composition of claim 1 , wherein the method further comprises initial steps of mixing a solution of ferric iron ions and one or more carboxylic acid ligands or carboxylate ligands and increasing the pH of the solution to cause formation of the colloidal suspension of the carboxylate ligand modified ferric iron hydroxide.

10. The composition of claim 9 , wherein the pH is increased by the addition of alkali, optionally wherein the alkali is sodium hydroxide.

11. The composition of claim 9 , wherein the pH is increased to a pH between 7.0 and 9.0.

12. The composition of claim 9 , wherein the pH is increased to a pH between 7.4 and 8.5.

13. The composition of claim 2 , wherein the carboxylate ligand modified ferric iron hydroxide in the colloidal suspension comprises a concentration of ferric iron between 20 mM and 1000 mM, a concentration of adipate between 10 mM and 150 mM, and a concentration of tartrate between 10 mM and 500 mM.

14. The composition of claim 13 , wherein the carboxylate ligand modified ferric iron hydroxide in the colloidal suspension comprises a concentration of ferric iron between 20 mM and 80 mM, a concentration of adipate between 10 mM and 40 mM, and a concentration of tartrate between 10 mM and 40 mM.

15. The composition of claim 13 , wherein the carboxylate ligand modified ferric iron hydroxide in the colloidal suspension comprises a concentration of ferric iron of about 40 mM, a concentration of adipate of about 20 mM, and a concentration of tartrate of about 20 mM.

16. The composition of claim 13 , wherein the carboxylate ligand modified ferric iron hydroxide in the colloidal suspension comprises a concentration of ferric iron of about 200 mM, a concentration of adipate of about 100 mM, and a concentration of tartrate of about 100 mM.

17. The composition of claim 1 , wherein the carboxylate ligand modified ferric iron hydroxide material comprises tartrate and/or tartaric acid ligands.

18. The composition of claim 1 , wherein the ratio of the volume of the water miscible non-aqueous solvent to the colloidal suspension of the carboxylate ligand modified ferric iron hydroxide is between 1:1 and 5:1.

19. The composition of claim 1 , wherein the water miscible non-aqueous solvent is ethanol.

20. The composition of claim 1 , wherein the drying step takes 24 hours or less at 45° C.

21. The composition of claim 1 , wherein the steps of agglomerating the suspension and recovering the agglomerated carboxylate ligand modified ferric iron hydroxide removes unreacted ferric iron ions (Fe3+), sodium chloride and/or one or more carboxylic acid ligands or carboxylate ligands from the carboxylate ligand modified ferric iron hydroxide.

22. The composition of claim 1 , where the carboxylate ligand modified ferric iron hydroxide material has a mean particle size between 1 and 10 nm.

23. The composition of claim 1 , wherein the metal-ligand bonding disrupts the structure of the carboxylate ligand modified ferric iron hydroxide material as determined using X-ray diffraction (XRD).

24. The composition of claim 23 , wherein the carboxylate ligand modified ferric iron hydroxide material has a structure that is consistent with ligand modified ferrihydrite collected by oven drying, wherein the structure is determined by electron energy-loss spectroscopy (EELS), and wherein the EELS spectrum comprises ferric iron and organic ligand-altered carbon and oxygen edges.

25. The composition of claim 1 , wherein the method further comprises a step of milling or micronizing the carboxylate ligand modified ferric iron hydroxide material.

26. The composition of claim 1 , wherein the method further comprises a step of formulating the carboxylate ligand modified ferric iron hydroxide material by mixing it with one or more pharmaceutically acceptable excipients.

27. The composition of claim 26 , wherein the method further comprises making tablets or capsules.

28. The composition of claim 26 , wherein the carboxylate ligand modified ferric iron hydroxide material is formulated for oral delivery.

29. The composition of claim 1 , wherein the optional substitution comprises one or more hydroxyl groups.

30. A composition comprising a carboxylate ligand modified ferric iron hydroxide material having a three dimensional polymeric structure in which the carboxylate ligands are non-stoichiometrically substituted for the oxo or hydroxy groups of the ferric iron hydroxide so that some of the ligand integrates into the solid phase by formal metal-ligand bonding,
wherein the three dimensional polymeric structure of the carboxylate ligand modified ferric iron hydroxide is such that the substitution of the oxo or hydroxy groups by the carboxylate ligands is random, and
wherein the

Assignees

• Res & Innovation Uk

Inventors

• Powell Jonathan Joseph
• Faria Nuno Jorge Rodrigues

Classifications

• A61K9/0095 Primary

  Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006) · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title

• A61K9/14

  Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)} · CPC title

• A23V2002/00

  Food compositions, function of food ingredients or processes for food or foodstuffs · CPC title

• A61K33/26

  Iron; Compounds thereof · CPC title